Skip to content
Screener

Price / book at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
7.2×+2.5×
United Community Banks logo
United Community BanksUCB
1.1×+0.1×
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
3.1×+0.7×
Summit Therapeutics logo
Summit TherapeuticsSMMT
26.9×-14.4×
Immunome logo
ImmunomeIMNM
4.2×+2.3×
Vera Therapeutics logo
Vera TherapeuticsVERA
5.7×+2.9×

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.11B+197%
Enterprise value$7.21B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Calculated from Immunovant, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026. Open the filing →

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064

FAQ

What is Immunovant, Inc.'s price / book?
Immunovant, Inc. (IMVT) reported price / book of 5.9× in Q1 2026.
How has Immunovant, Inc.'s price / book changed year-over-year?
Immunovant, Inc.'s price / book increased by 44.5% year-over-year, from 4.1× to 5.9×.
What is the long-term trend for Immunovant, Inc.'s price / book?
Over 5 years (2021 to 2026), Immunovant, Inc.'s price / book has grown at a 8.1% compound annual growth rate (CAGR), from 4× to 5.9×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.

Ask your AI about Immunovant, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude